Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

Description

The investigators will be evaluating bone marrow composition via magnetic resonance imaging in adolescents diagnosed with cystic fibrosis (CF) compared to healthy, matched controls. The investigators will also be assessing their bone mineral density via other imaging modalities, including dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). This longitudinal project will focus on abnormalities in bone marrow composition, and specifically whether adolescents with diagnosed with CF exhibit increased bone marrow fat, its association with bone mineral density (BMD) and the underlying pathophysiology, including glycemic control, inflammation, and bone turnover markers.

Conditions

Cystic Fibrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators will be evaluating bone marrow composition via magnetic resonance imaging in adolescents diagnosed with cystic fibrosis (CF) compared to healthy, matched controls. The investigators will also be assessing their bone mineral density via other imaging modalities, including dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). This longitudinal project will focus on abnormalities in bone marrow composition, and specifically whether adolescents with diagnosed with CF exhibit increased bone marrow fat, its association with bone mineral density (BMD) and the underlying pathophysiology, including glycemic control, inflammation, and bone turnover markers.

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

Condition
Cystic Fibrosis
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 13-20 years old
  • * Cystic fibrosis with pancreatic insufficiency
  • * Must have a stable treatment regimen, including CFTR modulator usage unchanged for the prior three months
  • * Liver transplant recipients will be eligible, as long as they are at least 1 year post-transplant and are no longer on Prednisone for immunosuppressive therapy
  • * Diagnosis of other chronic disease affecting bone health
  • * Active use (within the past 3 months) of medications that are known to affect skeletal metabolism
  • * CF exacerbation or glucocorticoid exposure within the prior 1 month
  • * Lung transplant

Ages Eligible for Study

13 Years to 20 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Boston Children's Hospital,

Rebecca Gordon, MD, PRINCIPAL_INVESTIGATOR, Boston Children's Hospital

Study Record Dates

2029-06-30